Drug developed for pancreatic cancer shows promise against most aggressive form of medulloblastoma
A drug that was developed to treat pancreatic cancer has now been shown to increase symptom-free survival in preclinical medulloblastoma models — all without showing signs of toxicity. Medulloblastoma is the most common malignant brain tumor in children. Survival rates vary according to which one of the four subtypes a patient has, but the worst … Read more
